In a pilot trial, 13 patients with recurrent/refractory neuroblastoma were treated with hu14.18K322A, GM-CSF, IL-2, and chemotherapy combined with an infusion of haploidentical NK cells resulting in a 61.5% response rate and 38.5% had stable disease [143]. Here, IL2 is linked to neuroblastoma.